Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Lee

Otolaryngology Boston, MA Medical Doctor

NPI 1437130267 CMS profile 245963

243 Charles St, Department Of Otolaryngology Meei, Boston, MA 02114

Open in the dashboard

General payments

$52,130

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$25,780

3 holdings reported · through program year 2025

Research they led as principal investigator

$36,411 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Daniel Lee of Boston, MA is reported in the CMS Open Payments database as having received $52,130 across 32 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,411 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $25,780 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,725 2
2024 General $5,929 19
2023 General $19,464 3
2022 General $37 2
2021 General $10,600 1
2020 General $4,088 1
2019 General $288 4
2023 Ownership $2,480 1
2021 Ownership $3,200 1
2020 Ownership $20,100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Lee
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Daniel Lee were reported at $11,725. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Daniel Lee Otolaryngology median Middle half National median
2019 $288 $194 $82–$512 $163
2020 $4,088 $118 $42–$280 $114
2021 $10,600 $167 $63–$444 $132
2022 $37 $216 $84–$545 $149
2023 $19,464 $235 $93–$588 $160
2024 $5,929 $280 $111–$699 $164
2025 $11,725 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. 3NT Medical $35,711 4 payments
  2. MED-EL Corporation $15,929 20 payments
  3. Grace Medical, Inc. $147 1 payment
  4. Medtronic Vascular, Inc. $127 1 payment
  5. KARL STORZ Endoscopy-America $120 1 payment
  6. Advanced Bionics, LLC $37 2 payments
  7. Acclarent, Inc $30 1 payment
  8. DePuy Synthes Sales Inc. $18 1 payment
  9. Covidien LP $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $37,411 5 payments
  2. Grant $10,000 1 payment
  3. Travel and Lodging $3,915 9 payments
  4. Food and Beverage $794 16 payments
  5. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. Mi1250 SYNCHRONY 2 FLEXsoft $13,067 15 payments
  2. BCI 602 Kit $13,067 15 payments
  3. ADHEAR Professional Kit $13,048 14 payments
  4. Peregrine Drivable ENT Scope $1,725 1 payment
  5. Colibri Micro ENT Scope $1,725 1 payment
  6. 3F $127 1 payment
  7. TELESCOPE,HOPKINS,30,3MM, 14CM $120 1 payment
  8. HIRES ULTRA CI HIFOCUS MS ELECTRODE $37 2 payments
  9. TruDi Navigation System $30 1 payment
  10. Teligen $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Otolaryngology: 297

Drug cost

$978

Median for Otolaryngology: $6,314

Branded share of claims

33.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofloxacin Generic 22 $935
Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid Brand 11 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$85,563

Medicare's payments for the services billed

Medicare patients

350

Average age 73

Services billed

704

208 women, 142 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 47%
Osteoporosis 26%
Ischemic heart disease 21%
Depression 21%
Diabetes 17%
Chronic kidney disease 17%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record